News

hdiv

TetraGenetics Receives Investment from JDRF T1D Fund

Read More
hdiv

TetraGenetics Announces Another Strategic Partnership with a Top Ten Pharmaceutical Company Program to Discover Ion Channel Antibodies for Pain

Read More
hdiv

TetraGenetics Awarded $1.5M Research and Development Grant by NIH

Read More
hdiv

TetraGenetics Launches Partnership Program For Discovery and Development of Therapeutic Monoclonal Antibodies

Read More
hdiv

TetraGenetics Announces Multi-Target Ion Channel Antibody Drug Discovery Partnership with MedImmune

Read More
hdiv

TetraGenetics Announces Partnership with Pfizer for SionX™ Technology to Express Ion Channel Drug Target

Read More
hdiv

TetraGenetics Announces Partnership with Amgen for Surface Antigen Target on an Exclusive Basis

Read More
hdiv

TetraGenetics Announces Phase II Funding from Gates Foundation for Malaria Vaccine

Read More
hdiv

“Producing Provocative Proteins” article published in BioCentury

Read More
hdiv

TetraGenetics Announces Results of Flu Vaccine Study

Read More
hdiv

TetraGenetics publishes article in BioPharm International Vaccine Supplement

Read More
hdiv

TetraGenetics introduces the TetraExpress™ manufacturing platform at BIO 2010

hdiv

A Phase I SBIR Small Business Catalyst (SBC) grant is awarded from the NIGMS to develop new methods for production of human mAbs using the TetraExpress™ platform

hdiv

TetraGenetics executes a license to key technology from the University of Georgia

hdiv

TetraGenetics, NEB and Berkeley scientists publish a study characterizing the secreted proteome of Tetrahymena thermophila

hdiv

Nobel Prize awarded to Greider, Blackburn and Szostak for discovery of telomeres and teleomerase